Logo image
Drugs, bugs, and MS: The interplay between disease-modifying therapy and gut microbiota
Journal article   Open access

Drugs, bugs, and MS: The interplay between disease-modifying therapy and gut microbiota

Neurology: Neuroimmunology and NeuroInflammation, Vol.6(1), e524
2019
DOI: 10.1212/NXI.0000000000000524
PMID: 30569001
url
https://doi.org/10.1212/NXI.0000000000000524View
Published (Version of record) Open Access

Abstract

MS is an inflammatory disease in which both genetic and environmental factors play roles in the predisposition to disease. A number of recent studies suggest that gut microbiota might be a potential environmental factor linked with the pathogenesis of MS. Trillions of bacteria residing in the human gut (gut microbiota) play an important role in maintaining a healthy state, and perturbation of the gut microbiota is associated with exacerbation and/or precipitation of MS. A number of recent studies have shown that patients with MS have gut dysbiosis characterized by altered levels of certain gut bacteria.1–5 Because MS is an inflammatory disease, it is hypothesized that gut bacteria enriched in patients with MS might possess proinflammatory properties, whereas those showing reduced relative abundance might be anti-inflammatory in nature.

Details

Metrics

Logo image